Previous 10 | Next 10 |
Our analysis concludes CLRB appears a worthwhile speculative investment at $1.15 per share primarily because the potential upside dramatically outweighs the risk of downside based on, among other things, the results of CLRB's Phase 2 trial (called CLOVER-1) of its CLR131 candidate therapy in p...
Intra-Cellular stock jumps as its bipolar trial delivers positive data Intra-Cellular Therapies Inc. (ITCI) announced positive top-line data from its Phase 3 clinical trial of its lead drug candidate lumateperone. The trial was designed to evaluate the potential of lumateperone as an ad...
FLORHAM PARK, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced James Caruso, president and CE...
Cellectar Biosciences ( CLRB +2.8% ) announced that a clinically meaningful 40% (6/15 patients) overall response rate (ORR) was observed in the CLOVER-1 Phase 2 study for CLR 131, in the subset of multiple myeloma (MM) patients, deemed triple class refractory who received ...
FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that a clinically meaningful 4...
Poster highlights the Phase 2a study data in relapsed or refractory lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM) Interim results show 100% overall response rate and a 75% major response rate FLORHAM PARK, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Cell...
CureVac (NASDAQ: CVAC ) +47% on making reasonable profit on COVID-19 vaccine. More news on: CureVac N.V., LMP Automotive Holdings, Inc., Microbot Medical Inc., Stocks on the move, , Read more ...
These Names Are On Analysts’ Lists Of Penny Stocks Right Now; Are They On Yours? Penny stocks aren’t just “short-term” movers or “lotto trades” as some might assume. If you’ve been a reader of our articles this year, you have come to learn tha...
Cellectar Biosciences (NASDAQ: CLRB ) : Q2 GAAP EPS of -$0.26 beats by $0.04 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the secon...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences,...
Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, develop...